Advances in kinase targeting: current clinical use and clinical trials

Area of Science:

• Pharmacological Research
• Drug Discovery
• Biochemistry

Background:

• Kinases (phosphotransferases) are a major focus in drug development.
• The success of imatinib (Gleevec®) in cancer treatment spurred further research.
• Kinase inhibitors are now explored for inflammatory, ophthalmological, CNS, and metabolic disorders.

Purpose of the Study:

• To review kinase drug targets and agents in current clinical trials.
• To analyze the landscape of kinase-targeted therapies across various indications.
• To provide an overview of the development of kinase inhibitors.

Main Methods:

• Analysis of established and clinical trial drug mechanisms of action.
• Utilization of private and public databases for drug information.
• Compilation of a dataset detailing over 3000 approved and experimental drugs.

Main Results:

• A vast number of kinase-targeting agents are in active clinical trials.
• Kinase inhibitors have expanded beyond cancer to other therapeutic areas.
• Significant ongoing development in kinase-targeted therapies for diverse diseases.

Conclusions:

• Kinases remain a highly significant target class in pharmaceutical research.
• Clinical trials showcase a broad spectrum of kinase inhibitors under investigation.
• The therapeutic potential of kinase-targeting drugs continues to expand rapidly.